Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

House Lawmakers Could Receive A Mountain Of Docs On US FDA Scientific Disagreements

Jan 05 2024

• By Derrick Gingery

paper mountain — The House committee wants administrative files related to all scientific disagreements at the FDA since 2018. • Source: Shutterstock

Related Content

US FDA’s Marks Was Frustrated About Slow Completion Of 2021 Comirnaty Review

Jan 25 2023

Dispute Resolution: Ardelyx Eyes Tenapanor Resubmission Following Successful Appeal To FDA

Jan 04 2023

Biden’s Trump Moment? COVID Booster Messaging Complicated After Top FDA Scientists Raise Doubts

Sep 14 2021

Former FDA Commissioner Hahn Faces Questions From House On Trump Interference, Other COVID Issues

Nov 24 2021

Sarepta’s DMD Gene Therapy Helped Across Accelerated Approval Finish Line By CBER’s Peter Marks

Jun 22 2023

Elevidys And The EMBARK Trial: Is Another Advisory Committee Meeting Coming?

Nov 01 2023

US FDA’s Top Two Vaccine Officials Announce Surprise Retirements

Sep 01 2021

US COVID-19 Vaccine Booster Plan Also Boosts Pressure On FDA

Aug 18 2021

How Can FDA Avoid Political Interference? More Independence, Fewer Appointees, GAO Says

Dec 18 2022

Renewed Political Pressure on Hydroxychloroquine for COVID Highlights Need For Independent US FDA

Jul 08 2020

Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate

Sep 20 2016

Related Companies

Sarepta Therapeutics, Inc.

Pfizer Inc.

BioNTech SE

Additional Topics

United States Coronavirus COVID-19 Leadership Politics Vaccines Review Pathway FDA Regulation BioPharmaceutical

More from Agency Leadership

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window